These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28669714)

  • 1. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
    Natfji AA; Ravishankar D; Osborn HMI; Greco F
    J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
    Maeda H
    Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
    Prabhakar U; Maeda H; Jain RK; Sevick-Muraca EM; Zamboni W; Farokhzad OC; Barry ST; Gabizon A; Grodzinski P; Blakey DC
    Cancer Res; 2013 Apr; 73(8):2412-7. PubMed ID: 23423979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
    Maeda H; Tsukigawa K; Fang J
    Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
    Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
    Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor targeting via EPR: Strategies to enhance patient responses.
    Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
    Nakamura H; Fang J; Maeda H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Evaluation of the Enhanced Permeability and Retention (EPR) Effect.
    Russell LM; Dawidczyk CM; Searson PC
    Methods Mol Biol; 2017; 1530():247-254. PubMed ID: 28150206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
    Fang J; Islam W; Maeda H
    Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
    Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
    Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving nanotherapy delivery and action through image-guided systems pharmacology.
    Ng TSC; Garlin MA; Weissleder R; Miller MA
    Theranostics; 2020; 10(3):968-997. PubMed ID: 31938046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine.
    Kirtane AR; Siegel RA; Panyam J
    J Pharm Sci; 2015 Mar; 104(3):1174-86. PubMed ID: 25583443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives.
    Sun R; Xiang J; Zhou Q; Piao Y; Tang J; Shao S; Zhou Z; Bae YH; Shen Y
    Adv Drug Deliv Rev; 2022 Dec; 191():114614. PubMed ID: 36347432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications.
    Durymanov M; Kamaletdinova T; Lehmann SE; Reineke J
    J Control Release; 2017 Sep; 261():10-22. PubMed ID: 28625673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.